CA2206736A1 - Aerosol formulations of peptides and proteins - Google Patents

Aerosol formulations of peptides and proteins

Info

Publication number
CA2206736A1
CA2206736A1 CA002206736A CA2206736A CA2206736A1 CA 2206736 A1 CA2206736 A1 CA 2206736A1 CA 002206736 A CA002206736 A CA 002206736A CA 2206736 A CA2206736 A CA 2206736A CA 2206736 A1 CA2206736 A1 CA 2206736A1
Authority
CA
Canada
Prior art keywords
peptides
proteins
aerosol formulations
surfactant
propellant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002206736A
Other languages
French (fr)
Other versions
CA2206736C (en
Inventor
Kjell Backstrom
Magnus Dahlback
Ann Johansson
Goran Kallstrand
Elisabet Lindqvist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra Aktiebolag
Kjell Backstrom
Magnus Dahlback
Ann Johansson
Goran Kallstrand
Elisabet Lindqvist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9404467A external-priority patent/SE9404467D0/en
Priority claimed from SE9502453A external-priority patent/SE9502453D0/en
Application filed by Astra Aktiebolag, Kjell Backstrom, Magnus Dahlback, Ann Johansson, Goran Kallstrand, Elisabet Lindqvist filed Critical Astra Aktiebolag
Publication of CA2206736A1 publication Critical patent/CA2206736A1/en
Application granted granted Critical
Publication of CA2206736C publication Critical patent/CA2206736C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

A pharmaceutical aerosol formulation comprising (a) a HFA propellant; (b) a pharmaceutically active polypeptide dispersible in the propellant; and (c) a surfactant which is a C8-C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide, which surfactant enhances the systemic absorption of the polypeptide in the lower respiratory tract.
CA002206736A 1994-12-22 1995-12-19 Aerosol formulations of peptides and proteins Expired - Fee Related CA2206736C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9404467-4 1994-12-22
SE9404467A SE9404467D0 (en) 1994-12-22 1994-12-22 Drug formulations
SE9502453A SE9502453D0 (en) 1995-07-06 1995-07-06 Drug formulations
SE9502453-5 1995-07-06
PCT/SE1995/001540 WO1996019197A1 (en) 1994-12-22 1995-12-19 Aerosol formulations of peptides and proteins

Publications (2)

Publication Number Publication Date
CA2206736A1 true CA2206736A1 (en) 1996-06-27
CA2206736C CA2206736C (en) 2007-05-22

Family

ID=26662195

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002206736A Expired - Fee Related CA2206736C (en) 1994-12-22 1995-12-19 Aerosol formulations of peptides and proteins

Country Status (33)

Country Link
US (1) US6524557B1 (en)
EP (2) EP0797431B1 (en)
JP (2) JP3862178B2 (en)
KR (1) KR100428281B1 (en)
CN (1) CN1088581C (en)
AR (1) AR002013A1 (en)
AT (1) ATE217787T1 (en)
AU (1) AU702879B2 (en)
BR (1) BR9510501A (en)
CA (1) CA2206736C (en)
CZ (1) CZ288145B6 (en)
DE (1) DE69526801T2 (en)
DK (1) DK0797431T3 (en)
EE (1) EE03590B1 (en)
ES (1) ES2176355T3 (en)
FI (1) FI119413B (en)
HK (1) HK1003503A1 (en)
HU (1) HU227790B1 (en)
IL (1) IL116458A (en)
IS (1) IS1810B (en)
MX (1) MX9704545A (en)
MY (1) MY120664A (en)
NO (1) NO316105B1 (en)
NZ (1) NZ298167A (en)
PL (1) PL182560B1 (en)
PT (1) PT797431E (en)
RU (1) RU2175866C2 (en)
SA (1) SA95160483B1 (en)
SK (1) SK284346B6 (en)
TR (1) TR199501669A1 (en)
TW (1) TW398978B (en)
UA (1) UA42047C2 (en)
WO (1) WO1996019197A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
MX9704550A (en) * 1994-12-22 1997-10-31 Astra Ab Aerosol drug formulations.
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
EP1019023B1 (en) * 1997-09-29 2003-05-07 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6180142B1 (en) * 1998-08-21 2001-01-30 The Regents Of The University Of California Reduction of surfactant inactivation in pulmonary surfactant therapy
MA25590A1 (en) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst ACTIVE AGENT FOR DRY POWDER DELIVERY
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1169053A1 (en) 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
EP1064934A1 (en) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
AU1189301A (en) * 1999-10-29 2001-05-14 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
AU4445201A (en) * 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001281113B2 (en) 2000-08-07 2006-07-20 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
JP4380988B2 (en) * 2000-11-30 2009-12-09 ヴェクトゥラ リミテッド Method for producing particles used in a pharmaceutical composition
ES2689704T3 (en) 2000-11-30 2018-11-15 Vectura Limited Particles for use in a pharmaceutical composition
ES2474199T3 (en) 2000-11-30 2014-07-08 Vectura Limited Pharmaceutical compositions for inhalation
JP2005501810A (en) 2001-03-22 2005-01-20 バテル メモリアル インスティチュート Liquid form for electrohydrodynamic spraying containing polymer and suspended particles
PT1372608E (en) * 2001-03-30 2008-01-04 Jagotec Ag Medical aerosol formulations
JP2004528339A (en) * 2001-04-26 2004-09-16 ネクター セラピューティクス Novel methods and compositions for delivering macromolecules to or through the respiratory tract
GB0114033D0 (en) * 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
DK1418890T3 (en) * 2001-08-16 2008-08-11 Baxter Int Propellant-based microparticle formulations
EP1944016A1 (en) 2001-08-16 2008-07-16 Baxter International Inc. Propellant-based microparticle formulatons
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
US7186402B2 (en) 2001-12-21 2007-03-06 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
ATE424186T1 (en) 2001-12-21 2009-03-15 3M Innovative Properties Co MEDICAL AEROSOL COMPOSITIONS CONTAINING A FUNCTIONALIZED POLYETHYLENE GLYCOL EXCIPIENT
DE10205087A1 (en) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrins as suspension stabilizers in pressure-liquefied blowing agents
US20030185762A1 (en) * 2002-03-22 2003-10-02 Cowan Siu Man L. Highly aqueous liquid carrier formulations
SE524990C2 (en) * 2002-04-12 2004-11-09 Microdrug Ag Preparation of therapeutic dry powder and method for splitting and spreading in the air of medical powder
SE525027C2 (en) * 2002-04-12 2004-11-16 Microdrug Ag Device comprising a powder air grinder
CA2495689A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006516545A (en) * 2003-02-04 2006-07-06 クリサリス テクノロジーズ インコーポレイテッド Perfluorocarbon and hydrofluorocarbon preparations and their production and use
PL1610822T5 (en) * 2003-04-02 2019-05-31 Ares Trading Sa Liquid or freeze-dried pharmaceutical formulations of fsh and/or lh together with the non-ionic surfactant poloxamer 188 and a bacteriostatic agent
EP1755720A1 (en) * 2004-05-20 2007-02-28 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
ES2546015T3 (en) * 2004-10-01 2015-09-17 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compounds that modulate THR actions and inhibit TRH degradation enzyme
CN1301747C (en) * 2004-11-30 2007-02-28 深圳市海王英特龙生物技术股份有限公司 Protein medicine microcapsule and inhalational aerosol thereof
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
BRPI0710503A2 (en) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
JP5102833B2 (en) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション Exendin fusion protein
CN101861311A (en) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 The indazole that the 5-pyridone replaces
JP2011504505A (en) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
KR101259246B1 (en) 2008-03-17 2013-04-29 디스커버리 라보라토리스, 인크. Ventilation circuit adaptor and proximal aerosol delivery system
CA2756690C (en) * 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
JP5671451B2 (en) * 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド Compositions and preparation processes for GnRH related compounds
EP2179760B1 (en) 2008-10-22 2013-02-27 Trudell Medical International Modular Aerosol Delivery System
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
KR20150116466A (en) 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 Bicyclic heterocyclic spiro compounds
AR075613A1 (en) * 2009-02-25 2011-04-20 Merrion Res Iii Ltd COMPOSITION AND SUPPLY OF BIFOSPHONATE DRUGS. TREATMENT METHOD
US20120270778A1 (en) * 2009-12-18 2012-10-25 Aegis Therapeutics Llc Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US8802058B2 (en) * 2010-04-19 2014-08-12 Gelmed, Llc Pharmaceutical compositions and methods for administering the same
JP2014501784A (en) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド Pharmaceutical composition of iron for oral administration
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
CA2850084C (en) * 2011-10-11 2020-07-07 Chiesi Farmaceutici S.P.A. Crystalline microparticles of a beta-agonist coated with a fatty acid
KR102276161B1 (en) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 Antibody formulations and methods
RU2657523C2 (en) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Pharmaceutical aerosol composition of protease inhibitors with ozone-preserving propellant and its preparation
ES2841933T3 (en) 2014-10-31 2021-07-12 Univ Monash Powder formulation
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
EA202091615A1 (en) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс INTRANASAL FORMULATIONS BASED ON EPINEPHRINE AND METHODS FOR TREATING THE DISEASE
CN113508111A (en) 2018-12-31 2021-10-15 西奈山伊坎医学院 Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (en) 1957-01-31 1957-04-11
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
GB1063512A (en) 1962-11-30 1967-03-30 Benger Lab Ltd Aerosols
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1230472A (en) 1967-07-10 1971-05-05
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1569611A (en) 1976-01-23 1980-06-18 Fisons Ltd Pelletised or granular medicament formulation
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
DE2750090A1 (en) * 1976-11-19 1978-06-01 Sandoz Ag NEW FORMS OF ADMINISTRATION FOR ORGANIC COMPOUNDS
FR2372632A1 (en) 1976-12-03 1978-06-30 Riker Laboratoires NEW HEPARIN-BASED MEDICINAL PRODUCT ADMINISTRATIVE BY TRACHEO-BRONCHIAL AND ALVEOLAR ROUTE
SE7812207L (en) 1977-12-01 1979-06-02 Welsh Nat School Med APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES
JPS6034925B2 (en) 1979-07-31 1985-08-12 帝人株式会社 Long-acting nasal preparation and its manufacturing method
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
SE438261B (en) * 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
JPS59163313A (en) 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
DD261096A1 (en) 1983-05-20 1988-10-19 Frithjof Von Rottkay PROCESS FOR THE INHALATIVE APPLICATION OF BIOLOGICALLY ACTIVE PEPTIDES
US4959358A (en) 1983-06-06 1990-09-25 Beth Israel Hospital Assn. Drug administration
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
DE3323389A1 (en) 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen MEDICINAL PRODUCTS ON THE MOUTH OF THE MOUTH, THE NOSE AND / OR THE VENICE ON THE BASIS OF HEPARIN AND TENSIDES
DE3326089A1 (en) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
JPS61267528A (en) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
SE448277B (en) * 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
CA1274774A (en) 1985-04-15 1990-10-02 Kenneth S. Su Method for administering insulin
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
JPS63500175A (en) 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド Liposome inhalation method and inhalation system
US4847298A (en) 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
SE453566B (en) * 1986-03-07 1988-02-15 Draco Ab POWDER INHALATOR DEVICE
JPS632932A (en) 1986-06-23 1988-01-07 Teijin Ltd Powdery composition for nasal administration
US4926852B1 (en) * 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
WO1988001165A1 (en) * 1986-08-11 1988-02-25 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
AU627147B2 (en) 1986-10-22 1992-08-20 Peter Alestrom Production of human parathyroid hormone from microorganisms
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8712176D0 (en) 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
NZ226557A (en) 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
JPH01117825A (en) 1987-10-28 1989-05-10 Sanwa Kagaku Kenkyusho Co Ltd Pharmaceutical for nasal cavity and paranasal sinuses administration and use, form and use tool thereof
EP0360340A1 (en) 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH02104531A (en) 1988-10-14 1990-04-17 Toyo Jozo Co Ltd Physiologically active peptide composition for nasal application
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
ATE138071T1 (en) 1989-02-17 1996-06-15 Liposome Co Inc LIPID AIDS FOR ADMINISTRATION THROUGH THE NOSE AND TOPICAL APPLICATION
IT8920486A0 (en) 1989-05-12 1989-05-12 Isf Spa PHARMACEUTICAL COMPOSITIONS.
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
JP2642486B2 (en) 1989-08-04 1997-08-20 田辺製薬株式会社 Ultrafine particle method for poorly soluble drugs
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
DE4003272A1 (en) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
EP0526481B1 (en) 1990-03-23 1995-04-26 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05963A (en) 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
JP3219096B2 (en) 1990-05-10 2001-10-15 ニコメド ファーマ エイエス Pharmaceutical preparations containing n-glycolfurols and n-ethylene glycols
GB9010742D0 (en) 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
JPH0441421A (en) 1990-06-07 1992-02-12 Taisho Pharmaceut Co Ltd Pulmonary absorbable composition
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
SE9002895D0 (en) 1990-09-12 1990-09-12 Astra Ab INHALATION DEVICES FOR DISPENSING POWDERS I
JPH04149126A (en) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp Pharmaceutical composition for transmucous administration
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP3507486B2 (en) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド Intrapulmonary administration of granulocyte colony-stimulating factor
PT656207E (en) 1991-06-10 2001-11-30 Schering Corp AEROSOLS FORMULATIONS WITHOUT CHLOROFLUOROCARBONETS
AU662919B2 (en) * 1991-07-02 1995-09-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
WO1993013752A1 (en) 1992-01-21 1993-07-22 Sri International Improved process for preparing micronized polypeptide drugs
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
CA2094217A1 (en) 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
WO1993025198A1 (en) 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
CA2145418A1 (en) 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
EP0681491B1 (en) * 1993-01-29 2000-12-13 Aradigm Corporation Intrapulmonary delivery of hormones
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
BE1006873A6 (en) 1993-03-26 1995-01-10 Merkus Franciscus W H M Administration for drafting nasal insulin delivery.
WO1994023772A2 (en) * 1993-04-06 1994-10-27 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9314614D0 (en) * 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
ES2218543T3 (en) 1994-03-07 2004-11-16 Nektar Therapeutics PROCEDURE AND PREPARATION FOR THE ADMINISTRATION OF INSULIN BY PULMONARY ROUTE.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
SE9404468D0 (en) * 1994-12-22 1994-12-22 Astra Ab Powder formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution

Also Published As

Publication number Publication date
US6524557B1 (en) 2003-02-25
CN1171046A (en) 1998-01-21
PL182560B1 (en) 2002-01-31
RU2175866C2 (en) 2001-11-20
WO1996019197A1 (en) 1996-06-27
CA2206736C (en) 2007-05-22
HUT77701A (en) 1998-07-28
MY120664A (en) 2005-11-30
CZ194597A3 (en) 1997-10-15
FI972657A0 (en) 1997-06-19
SK284346B6 (en) 2005-02-04
UA42047C2 (en) 2001-10-15
SA95160483B1 (en) 2005-04-19
FI972657A (en) 1997-06-19
JPH10510827A (en) 1998-10-20
NO972781D0 (en) 1997-06-16
BR9510501A (en) 1998-01-13
AU4359196A (en) 1996-07-10
JP2006137776A (en) 2006-06-01
SK81397A3 (en) 1997-11-05
EE03590B1 (en) 2002-02-15
EE9700137A (en) 1997-12-15
NO972781L (en) 1997-06-16
MX9704545A (en) 1997-10-31
JP3862178B2 (en) 2006-12-27
FI119413B (en) 2008-11-14
ES2176355T3 (en) 2002-12-01
CN1088581C (en) 2002-08-07
KR100428281B1 (en) 2004-06-16
CZ288145B6 (en) 2001-05-16
ATE217787T1 (en) 2002-06-15
EP0797431B1 (en) 2002-05-22
NO316105B1 (en) 2003-12-15
AU702879B2 (en) 1999-03-11
AR002013A1 (en) 1998-01-07
IL116458A (en) 2001-01-11
PL320824A1 (en) 1997-11-10
DE69526801D1 (en) 2002-06-27
NZ298167A (en) 1999-08-30
HU227790B1 (en) 2012-03-28
IS4496A (en) 1997-06-04
EP1180365A2 (en) 2002-02-20
IL116458A0 (en) 1996-03-31
DK0797431T3 (en) 2002-08-19
TR199501669A1 (en) 1997-03-21
TW398978B (en) 2000-07-21
DE69526801T2 (en) 2003-01-09
EP0797431A1 (en) 1997-10-01
IS1810B (en) 2002-04-30
HK1003503A1 (en) 1998-10-30
EP1180365A3 (en) 2003-06-25
PT797431E (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CA2206736A1 (en) Aerosol formulations of peptides and proteins
MY131733A (en) Aerosol drug formulations
WO1998013031A3 (en) Medicinal aerosol formulations comprising budesonide
NZ236823A (en) Topical pharmaceutical and cosmetic compositions containing a salt of cholanic acid, a lipid and optionally a pharmaceutically or cosmetically active substance
CA2381329A1 (en) Medicaments
CA2317999A1 (en) Pharmaceutical formulation of fluticasone propionate
AU3038197A (en) Aerosol formulations
CA2125667A1 (en) Fluorocarbon aerosol medicaments
AU5306486A (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
EP0995434A3 (en) Medicinal aerosol formulations
CA2111002A1 (en) Non-Chlorofluorocarbon Aerosol Formulations
CA2311450A1 (en) Pharmaceutical aerosol compositions
EP1731140A3 (en) Medicinal aerosol formulation
CA2416403A1 (en) A medicinal aerosol formulation
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
CA2213774A1 (en) Pharmaceutical compositions and devices for their administration
AU1269488A (en) Phenoxycarboxylic acid and herbicide comprising it as active ingredient
CA2285985A1 (en) A method for preparing aqueous liposomal compositions comprising an active ingredient which is highly insoluble in water
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
TH22661B (en) Aerosol formula of peptide and protein
EP0341661A3 (en) Peptide-drug compositions containing alpha-aminoboronic acid derivatives
AU1534501A (en) Pharmaceutical formulations of salmeterol
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
CA2215680A1 (en) Prilocaine and hydrofluorocarbon aerosol preparations
TH23425A (en) Aerosol drug formulation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131219